Veru Inc
$ 3.10
3.33%
09 Jun - close price
- Market Cap 52,184,000 USD
- Current Price $ 3.10
- High / Low $ 3.43 / 2.98
- Stock P/E N/A
- Book Value 2.31
- EPS -0.80
- Next Earning Report 2026-08-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.46 %
- ROE -0.52 %
- 52 Week High 7.40
- 52 Week Low 2.05
About
Veru Inc., an oncology biopharmaceutical company, focuses on the development of drugs for the treatment of cancers. The company is headquartered in Miami, Florida.
Analyst Target Price
$24.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-02-11 | 2025-12-17 | 2025-08-12 | 2025-05-08 | 2025-02-13 | 2024-12-16 | 2024-08-08 | 2024-04-01 | 2024-02-14 | 2023-12-08 | 2023-08-10 |
| Reported EPS | -0.13 | -0.26 | 0.09 | -0.53 | -0.6 | -0.71 | -0.052 | -0.76 | -0.91 | -0.08 | -2.7 | -1.24 |
| Estimated EPS | -0.28 | -0.47 | -0.0567 | -0.5 | -0.5 | -0.8 | -0.08 | -0.6 | -1.5 | -0.1 | -2.35 | -2.9 |
| Surprise | 0.15 | 0.21 | 0.1467 | -0.03 | -0.1 | 0.09 | 0.028 | -0.16 | 0.59 | 0.02 | -0.35 | 1.66 |
| Surprise Percentage | 53.5714% | 44.6809% | 258.7302% | -6% | -20% | 11.25% | 35% | -26.6667% | 39.3333% | 20% | -14.8936% | 57.2414% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-12 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.32 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.06 | $0.06 | $0.06 | $0.06 | $0.05 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VERU
2026-06-06 21:10:10
Novo Nordisk has partnered with Veru Inc. in a clinical supply agreement to provide Wegovy for a Phase 2b obesity trial in older adults, focusing on combination therapy. This collaboration is considered an underappreciated development by investors, as it is outside Novo Nordisk’s regular trial program and financial disclosures. The agreement also includes a right of first negotiation, allowing Novo Nordisk to maintain future collaboration options with Veru.
2026-06-06 06:40:08
Novo Nordisk has entered a clinical supply agreement with Veru Inc. to provide Wegovy for a pivotal Phase 2b obesity trial in older adults, exploring a combination therapy approach. This collaboration, which includes a right of first negotiation for Novo Nordisk, is not yet widely discussed in investor circles as it sits outside Novo Nordisk’s standard financial disclosures and trial programs. The development brings a new clinical angle to Wegovy's potential usage in a specific patient segment and offers optionality for future partnership.
2026-06-05 21:40:08
Veru Inc. (NASDAQ: VERU) announced a clinical supply agreement with Novo Nordisk AS (NYSE: NVO), causing its stock price to surge over 160%. Under the deal, Veru will evaluate its drug candidate enobosarm in conjunction with Novo Nordisk’s Wegovy in the Phase 2b PLATEAU trial for older adults with obesity. Veru retains full global development and commercialization rights to enobosarm and has granted Novo Nordisk a right of first negotiation for future combinations with GLP-1 therapies.
2026-06-05 11:38:44
This article identifies three intriguing penny stocks: Veru (VERU), Health Catalyst (HCAT), and trivago (TRVG). Veru is a late-clinical stage biopharmaceutical company with strong financial health despite being pre-revenue. Health Catalyst, a healthcare data and analytics company, faces financial challenges but has a long cash runway. Trivago, a hotel search platform, has recently become profitable, is debt-free, and shows solid liquidity.
2026-06-05 09:41:01
Veru has announced a supply agreement with Novo Nordisk to provide Veru's investigational drug, enobosarm, for a planned Phase 2B clinical study in obesity. This collaboration marks a significant development for Veru, as its shares surged following the news, indicating positive investor reaction to the partnership with a leading pharmaceutical company in the obesity market. The agreement could potentially expand enobosarm's therapeutic applications beyond its previous focus.
2026-06-04 18:10:10
Veru Inc. (VERU) is a biopharmaceutical company focused on developing oral therapies for cardiometabolic dysfunction and inflammation, with a pipeline centered on enobosarm for high-quality weight loss and sabizabulin for inflammatory risk in cardiovascular disease. The company's investment profile is highly dependent on the success of its late-stage clinical trials. This page provides financial data, key ratios, and recent news related to VERU.
